Advertisement: KISS
RealVNC mid-banner general
RealVNC mid banner careers
Advertisement: Mobas mid banner
Advertisement: Cambridge Network
ARM Innovation Hub
Advertisement: BKL
Advertisement: Barclays Eagle Labs
8 January, 2018 - 11:06 By Tony Quested

Robotics pioneer scales into new flagship Cambridge HQ

Cambridge Medical Robotics, which is developing a unique robot for micro-surgery, is scaling at such a rapid rate that it is developing a new 42,000 sq ft UK headquarters to the north of the city.

From a standing start, CMR has more than doubled in size in the past year and grown to more than 140 staff. The company anticipates further strong growth through 2018.

It is relocating from Madingley to the newly developed Evolution Business Park just off junction 33 of the A14 between Milton and Impington. CMR expects the new building to be complete within a year.

Underlining its commitment to the UK, CMR will house its entire company –including engineering, research, manufacturing, clinical and commercial teams – under one roof. The space will also include laboratories, test and final assembly facilities and a demonstration operating room.

CMR has developed Versius, a surgical robot designed to meet the complex requirements of laparoscopic surgery and has filed more than 150 patents throughout its development.

Versius, inspired by the human arm, has remarkable dexterity, flexibility and reach, to enable a new paradigm in surgical experience in support of CMR’s aim of making minimal access surgery available to all.

Martin Frost, CMR’s CEO, said: “Cambridge is the innovation capital of Europe so it’s an ideal place for us to build our next generation product; one that will bring the benefits of minimal access surgery to millions of people worldwide.

“There are few places in the world where you can find all the skills you need to develop and commercialise such an exciting medical device as the Versius robot, but the UK, and more specifically Cambridge, is definitely one of them.

“This is a significant infrastructure investment in CMR, reflecting the momentum of the company, the confidence of its shareholders and the global market demand for Versius.”

Advertisement: Barclays Eagle Labs

Newsletter Subscription

Stay informed of the latest news and features